FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease
Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...
Dr. Frank Cortazar Heads Up New York Nephrology Vasculitis and Glomerular Center
Frank B. Cortazar, MD, and Jorge Cerda, MD Frank B. Cortazar, MD, has been named director of a new vasculitis center in the Albany, New York, area. Dr. Cortazar will oversee both clinical and research activities at the New York Nephrology Vasculitis and Glomerular Center, which opened August 1. There…...
Early VF-Funded Study Paves Way for New ANCA Vasculitis Clinical Trial
More than a decade ago, Donna O’Dell Bunch, PhD, was co-investigator in a Vasculitis Foundation-funded trial that studied changes in B cells (white blood cells that form antibodies) in patients with ANCA-associated vasculitis, and the medical implications of those changes on the disease. The findings from that 2007 clinical trial,…...
